双功能铜化剂能够减少Aβ聚合和Aβ诱导的氧化应激
Olga Krasnovskaya1, Daniil Abramchuk1, Alexander Vaneev1,2
1Chemistry Department, Lomonosov Moscow State University, Leninskie gory 1,3, Moscow 119991, Russia.
ACS omega
|November 4, 2024
概括
一种新型化合物Alz-5有效地防止β-粉样蛋白 (Aβ) 聚合,并降低神经毒性. 这种抗氧化剂在阿尔茨海默病研究中显示出抑制Aβ聚合的巨大潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 的特点是β-粉样蛋白 (Aβ) 聚合.
- Aβ聚合物有助于神经毒性和细胞功能障碍.
- 铜化是一种潜在的AD治疗策略.
研究的目的:
- 合成和评估用于抑制Aβ聚合的双功能铜合剂.
- 为了研究化合物Alz-5的神经保护性和抗胺基因性质.
- 评估Alz-5对Aβ受影响细胞的生物物理性质的影响.
主要方法:
- 合成五种双功能铜合剂 (Alz-1-5).
- 在Aβ42受影响的SH-SY5Y细胞中使用Pt-纳米电极技术评估抗氧化活性.
- 通过原子力显微镜 (AFM) 在Aβ42纤维上对抗粉原性质的评估.
- 在Aβ42-和Alz-5处理的SH-SY5Y细胞上使用Young的模量映射分析细胞机械性质.
主要成果:
- Alz-5显示出显著的抗氧化活性,减少Aβ42受影响细胞中的活性氧物种.
- AFM数据证实了Alz-5对Aβ42纤维的抗粉原作用.
- 的模量映射显示,Alz-5降低了由Aβ42.2诱导的细胞刚性.
- 阿尔兹-5呈现出低细胞毒性.
结论:
- 阿尔兹-5是一种有前途的双功能铜化剂,具有强大的抗氧化和抗粉原性质.
- Alz-5有效地减轻了Aβ诱导的神经毒性和细胞性.
- 这些发现支持Alz-5作为阿尔茨海默病的潜在治疗剂.
更多相关视频
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
9.1K
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
7.9K
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
